Abstract
Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1785-1796 |
| Number of pages | 12 |
| Journal | Future Medicinal Chemistry |
| Volume | 2 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2010 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
- Molecular Medicine
Cite this
Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance. / Yamada, Eijiro; Lee, Ting Wen A; Pessin, Jeffrey E.; Bastie, Claire C.
In: Future Medicinal Chemistry, Vol. 2, No. 12, 12.2010, p. 1785-1796.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance
AU - Yamada, Eijiro
AU - Lee, Ting Wen A
AU - Pessin, Jeffrey E.
AU - Bastie, Claire C.
PY - 2010/12
Y1 - 2010/12
N2 - Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.
AB - Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.
UR - http://www.scopus.com/inward/record.url?scp=78650217374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650217374&partnerID=8YFLogxK
U2 - 10.4155/fmc.10.264
DO - 10.4155/fmc.10.264
M3 - Article
C2 - 21428801
AN - SCOPUS:78650217374
VL - 2
SP - 1785
EP - 1796
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
SN - 1756-8919
IS - 12
ER -